

A pilot study to estimate the effect-size and possible selection criteria for dexamphetamine treatment during rehabilitation after acute stroke

Submission date 12/09/2003	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2003	Overall study status Stopped	<input type="checkbox"/> Protocol
Last Edited 27/07/2009	Condition category Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dagmar Long

Contact details

Care of the Elderly
St Luke's Hospital
Little Horton Lane
Bradford
United Kingdom
BD5 0NA

Additional identifiers

Protocol serial number

N0050119120

Study information

Scientific Title

Study objectives

Dexamphetamine has repeatedly been shown to enhance recovery after experimental brain injury in animal models. Our aim is to see whether dexamphetamine, given with rehabilitation treatment early after a stroke, is able to improve the recovery of limb weakness and, if so, to see which groups of patients respond best.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised double blind placebo controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiovascular: Stroke

Interventions

This is a placebo-controlled, double-blind, randomised pilot study based within two rehabilitation stroke units. Eligible patients will be randomised to receive either dexamphetamine or placebo, with two-thirds of the subjects receiving dexamphetamine. The medication will be given as a capsule by mouth about 1 h before a 60 min session of rehabilitation. The rehabilitation treatment will be provided in the standard way except that rehabilitation sessions will be timed to occur during the period of peak effect of the study medication.

Measurements of recovery will assess residual weakness and disability and will be made by the same health-trained research assistant at 3 and 6 weeks after recruitment and at 3 months after the stroke.

Added 27/07/09: trial was stopped due to lack of funding.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

dexamphetamine

Primary outcome(s)

The extent to which a subject's weakness has recovered at 3 months after the stroke. Interim assessments will occur at 3 and 6 weeks after beginning the trial medication. Assessment of recovery will document residual weakness of the affected arm, trunk and leg (using the Rivermead motor assessment scale) and the subject's degree of independence in basic activities of daily living (using the Barthel Index). In parallel, the subjects mood state will be assessed for depression and lack of motivation.

Key secondary outcome(s)

Not provided at time of registration

Completion date

16/10/2004

Reason abandoned (if study stopped)

Lack of funding

Eligibility

Key inclusion criteria

All patients aged 18 years and over newly admitted to the stroke units in Bradford and Leeds will be assessed by a research assistant for potential recruitment.

Eligible subjects will

1. have had a new stroke resulting in a right or left-sided weakness of sufficient severity to require an anticipated minimum 4-week stay on the stroke unit.
- 2, have a Computed Tomography (CT) scan to exclude intracranial haemorrhage
3. be medically stable and able to participate in daily rehabilitation.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. unable to understand language as a result of stroke
2. any memory impairment (pre-existing or as a consequence of the stroke)
3. stable heart disease and untreated high blood pressure
4. any psychiatric treatment within the past 5 years or a past history of drug or alcohol dependence.

Date of first enrolment

16/10/2002

Date of final enrolment

16/10/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Care of the Elderly

Bradford

United Kingdom

BD5 0NA

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Bradford Hospitals NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration